UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2024
__________________
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(800 ) 561-4148
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
__________________
(Former name or former address, if changed since last report)
__________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 2.02. Results of Operations and Financial Condition
On November 7, 2024, Abacus Life, Inc. (Abacus or Company) announced the results of its operations and its financial condition for the quarterly period ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” with the U.S. Securities and Exchange Commission or otherwise incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
| Exhibit Number | Exhibit Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL). | |||||||
Forward Looking Statements
This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Abacus’ public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Abacus’ most recent annual report on Form 10-K, as amended, and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Abacus’ other filings with the SEC, including those contained in the final prospectus and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements represent Abacus’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Abacus explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abacus Life, Inc. | ||||||||
| (Registrant) | ||||||||
| Date: November 7, 2024 | By: | /s/ Jay Jackson | ||||||
| Name: | Jay Jackson | |||||||
| Title: | Chief Executive Officer | |||||||
ABACUS LIFE REPORTS THIRD QUARTER 2024 RESULTS
- Delivered Continued Revenue and Profitability Growth While Executing on Strategic Initiatives -
- Third Quarter 2024 Total Revenue Grows 33% Year-over-Year to $28.1 Million -
- Due to Non-Cash Increase in Warrant Liability of $8.7M; GAAP Net Loss of $5.1M -
- Adjusted Net Income Grows 65% Year-over-Year to $14.9 Million -
- Adjusted EBITDA Grows 54% Year-over-Year to $16.7 Million -
ORLANDO, Fla. – November 7, 2024 – Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today reported results for the third quarter ended September 30, 2024.
“It was another great quarter for Abacus as we continued to deliver meaningful growth and profitability, while we successfully executed on our long-term strategy,” said Jay Jackson, Chief Executive Officer of Abacus. “Along with our excellent results, we are thrilled with the significant advancements we have made with our ABL Tech platform, which already serves over 20 clients, with 23 more either committed or in negotiations, in just eight months since launch. We also made substantial progress in terms of our announced acquisitions of Carlisle Management and FCF Advisors, which together will add about $2.6 billion in assets under management to our portfolio. We expect both deals to close by the end of the fourth quarter, subject to regulatory approval. Additionally, we partnered in the quarter with Lorisco to launch PREADISAN™, a revolutionary health prediction and actuarial technology tool, which will enable us to offer personalization in longevity forecasting, as well as highly tailored financial solutions for our clients. As we close out 2024, we remain well positioned to deliver sustained growth and profitability, thereby creating long-term value for our stockholders.”
Third Quarter 2024 Highlights
-Total revenue for the third quarter of 2024 grew 33% to $28.1 million, compared to $21.1 million in the prior-year period. The increase was primarily driven by higher active management revenue, increased capital deployed and more policies sold directly to third parties.
-Origination capital deployment for the third quarter of 2024 was $93.2 million, compared to $56.4 million in the prior-year period; number of policy originations for the third quarter of 2024 grew 54% to 278, compared to 181 in the prior-year period.
-GAAP net loss attributable to shareholders for the third quarter of 2024 was $5.1 million, compared to net income of $0.9 million in the prior-year period, primarily driven by a non-cash $7.8 million increase in loss on change in fair value of warrant liability, a $1.8 million increase in expenses related to employee stock compensation and a $1.5 million increase in interest expense.
-Adjusted net income (a non-GAAP financial measure) for the third quarter of 2024 grew 65% to $14.9 million, compared to $9.0 million in the prior-year period. Adjusted diluted earnings per share for the third quarter of 2024 was $0.20, compared to $0.14 in the prior-year period.
-Adjusted EBITDA (a non-GAAP financial measure) for the third quarter of 2024 grew 54% to $16.7 million, compared to $10.8 million in the prior-year period. Adjusted EBITDA margin (a non-GAAP financial measure) for the third quarter of 2024 was 59.2%, compared to 51.1% in the prior-year period.
-Annualized return on invested capital (ROIC) (a non-GAAP financial measure) for the third quarter of 2024 was 21%.
-Annualized Return on equity (ROE) (a non-GAAP financial measure) for the third quarter of 2024 was 23%.
Liquidity and Capital
As of September 30, 2024, the Company had cash and cash equivalents of $19.4 million, balance sheet policy assets of $274.4 million and outstanding long-term debt of $166.5 million.
Webcast and Conference Call
A webcast and conference call to discuss the Company’s results will be held today beginning at 5:00 p.m. (Eastern Time). A live webcast of the conference call will be available on Abacus’ investor relations website at ir.abacuslife.com. The dial-in number for the conference call is (800) 267-6316 (toll-free) or (203) 518-9783 (international), followed by the required Conference ID: ABACUS. Please dial the number 10 minutes prior to the scheduled start time.
A webcast replay of the call will be available at ir.abacuslife.com for one year following the call.
Non-GAAP Financial Information
Adjusted Net Income, a non-GAAP financial measure, is defined as net income (loss) attributable to Abacus adjusted for non-controlling interest income, amortization, change in fair value of warrants and non-cash stock-based compensation and the related tax effect of those adjustments. Management believes that Adjusted Net Income is an appropriate measure of operating performance because it eliminates the impact of expenses that do not relate to business performance. A reconciliation of Adjusted Net Income to Net income attributable to Abacus, the most directly comparable GAAP measure, appears below.
Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to Abacus adjusted for depreciation expense, amortization, interest expense, income tax and other non-cash and certain non-recurring items that in our judgement significantly impact the period-over-period assessment of performance and operating results that do not directly relate to business performance within Abacus’ control. A reconciliation of Adjusted EBITDA to Net income attributable to Abacus Life, the most directly comparable GAAP measure, appears below.
Adjusted EBITDA margin, a non-GAAP financial measure, is defined as Adjusted EBITDA divided by Total revenues. A reconciliation of Adjusted EBITDA margin to Net income margin, the most directly comparable GAAP measure, appears below.
Annualized return on invested capital (ROIC), a non-GAAP financial measure, is defined as Adjusted net income for the quarter divided by the result of Total Assets less Intangible assets, net, Goodwill and Current Liabilities multiplied by four. ROIC is not a measure of financial performance under GAAP. We believe ROIC should be considered in addition to, not as a substitute for, operating income or loss, net income or loss, cash flows provided by or used in operating, investing and financing activities or other income statement or cash flow statement line items reported in accordance with GAAP.
Annualized return on equity (ROE), a non-GAAP financial measure, is defined as Adjusted net income divided by total shareholder equity multiplied by four. ROE is not a measure of financial performance under GAAP. We believe ROE should be considered in addition to, not as a substitute for, operating income or loss, net income or loss, cash flows provided by or used in operating, investing and financing activities or other income statement or cash flow statement line items reported in accordance with GAAP. The below table presents our calculation of ROE.
Forward-Looking Statements
All statements in this press release (and oral statements made regarding the subjects of this press release) other than historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Abacus. Forward-looking information includes but is not limited to statements regarding: Abacus’s financial and operational outlook; Abacus’s operational and financial strategies, including planned growth initiatives and the benefits thereof, Abacus’s ability to successfully effect those strategies, and the expected results therefrom. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “expect,” “intend,” “anticipate,” “goals,” “prospects,” “will,” “would,” “will continue,” “will likely result,” and similar expressions (including the negative versions of such words or expressions).
While Abacus believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward-looking statements include, but are not limited to: the fact that Abacus’s loss reserves are bases on estimates and may be inadequate to cover its actual losses; the failure to properly price Abacus’s insurance policies; the geographic concentration of Abacus’s business; the cyclical nature of Abacus’s industry; the impact of regulation on Abacus’s business; the effects of competition on Abacus’s business; the failure of Abacus’s relationships with independent agencies; the failure to meet Abacus’s investment objectives; the inability to raise capital on favorable terms or at all; the effects of acts of terrorism; and the effectiveness of Abacus’s control environment, including the identification of control deficiencies.
These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties set forth in documents filed by Abacus with the U.S. Securities and Exchange Commission from time to time, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and subsequent periodic reports. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Abacus cautions you not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus does not give any assurance that it will achieve its expectations.
About Abacus
Abacus is a pioneering global alternative asset manager and market maker specializing in uncorrelated financial products. The company leverages its proprietary, cutting-edge longevity data and actuarial technology to purchase life insurance policies from consumers seeking liquidity. This creates a high-return asset class uncorrelated to market fluctuations for institutional investors.
With nearly $3 billion in assets under management, including pending acquisitions, Abacus is the only publicly traded global alternative asset manager focused on lifespan-based financial products.
Abacus is expanding its leading expertise in longevity and lifespan into new growth areas:
•ABL Wealth- Leverages decades of data and proprietary algorithms to offer longevity-based wealth management platforms that enable financial advisors to create customized plans and provide access to uncorrelated investments.
•ABL Tech - A groundbreaking technology service that delivers advanced real-time data tracking and analysis for pension funds, governments, insurance companies, retirement associations, and more.
Through each new channel, Abacus is revolutionizing the future of asset management and financial planning, centered on longevity and lifespan.
www.Abacuslife.com
Contact:
Investor Relations
Robert F. Phillips – SVP Investor Relations and Corporate Affairs
rob@abacuslife.com
(321) 290-1198
David Jackson – IR/Capital Markets Associate
djackson@abacuslife.com
(321) 299-0716
Abacus Life Public Relations
press@abacuslife.com
ABACUS LIFE, INC. Consolidated Balance Sheets
September 30, 2024 (unaudited) | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ 19,409,615 | $ 25,588,668 | |||||||||
| Equity securities, at fair value | 3,019,055 | 2,252,891 | |||||||||
| Accounts receivable | 2,232,432 | 2,149,111 | |||||||||
| Accounts receivable, related party | 83,498 | 79,509 | |||||||||
| Due from affiliates | 1,279,099 | 1,007,528 | |||||||||
| Income tax receivable | 2,702,103 | — | |||||||||
| Prepaid expenses and other current assets | 2,070,875 | 699,127 | |||||||||
| Total current assets | 30,796,677 | 31,776,834 | |||||||||
| Property and equipment, net | 888,519 | 400,720 | |||||||||
| Intangible assets, net | 24,653,141 | 29,623,130 | |||||||||
| Goodwill | 139,930,190 | 140,287,000 | |||||||||
| Operating right-of-use assets | 2,033,538 | 1,893,659 | |||||||||
| Life settlement policies, at cost | 1,071,172 | 1,697,178 | |||||||||
| Life settlement policies, at fair value | 273,249,493 | 122,296,559 | |||||||||
| Available-for-sale securities, at fair value | 1,185,740 | 1,105,935 | |||||||||
| Other investments, at cost | 1,850,000 | 1,650,000 | |||||||||
| Other assets | 1,650,698 | 998,945 | |||||||||
| Equity securities, at fair value | — | 96,107 | |||||||||
| TOTAL ASSETS | $ 477,309,168 | $ 331,826,067 | |||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Current portion of long-term debt, at fair value | $ 13,730,026 | $ 13,029,632 | |||||||||
| Accrued expenses | 2,535,277 | 4,354,225 | |||||||||
| Accounts payable | — | — | |||||||||
| Operating lease liabilities | 413,071 | 118,058 | |||||||||
| Due to affiliates | — | 5,236 | |||||||||
| Due to former members | — | 1,159,712 | |||||||||
| Contract liabilities, deposits on pending settlements | 924,083 | 507,000 | |||||||||
| Accrued transaction costs | 2,600,000 | — | |||||||||
| Other current liabilities | 3,659,891 | 3,400,734 | |||||||||
| Income taxes payable | — | 751,734 | |||||||||
| Total current liabilities | 23,862,348 | 23,326,331 | |||||||||
| Long-term debt, related party | 12,157,258 | 37,653,869 | |||||||||
| Long-term debt, net | 57,996,997 | 33,818,090 | |||||||||
| Long-term debt, at fair value, net | 96,358,740 | 55,318,923 | |||||||||
| Operating lease liabilities | 1,860,736 | 1,796,727 | |||||||||
| Deferred tax liability | 12,003,461 | 9,199,091 | |||||||||
| Warrant liability | 15,130,000 | 6,642,960 | |||||||||
| TOTAL LIABILITIES | 219,369,540 | 167,755,991 | |||||||||
| COMMITMENTS AND CONTINGENCIES (Note 12) | |||||||||||
| STOCKHOLDERS' EQUITY | |||||||||||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding | — | — | |||||||||
| Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 75,484,567 and 63,388,823 shares issued at September 30, 2024 and December 31, 2023, respectively | 7,576 | 6,339 | |||||||||
| Treasury stock - at cost; 1,048,226 and 146,650 shares repurchased at September 30, 2024 and December 31, 2023, respectively | (12,025,137) | (1,283,062) | |||||||||
| Additional paid-in capital | 309,655,378 | 199,826,278 | |||||||||
| Accumulated deficit | (39,639,373) | (34,726,135) | |||||||||
| Accumulated other comprehensive income | 32,721 | 108,373 | |||||||||
| Noncontrolling interest | (91,537) | 138,283 | |||||||||
| Total stockholders' equity | 257,939,628 | 164,070,076 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 477,309,168 | $ 331,826,067 | |||||||||
[1] The 2023 number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of Abacus Life, Inc. as a result of the Business Combination.
ABACUS LIFE, INC. Interim Unaudited Consolidated Statement of Operations
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| REVENUES: | |||||||||||||||||||||||
| Portfolio servicing revenue | $ 116,386 | $ 224,569 | $ 539,209 | $ 814,626 | |||||||||||||||||||
| Active management revenue | 26,967,575 | 18,926,144 | 73,778,331 | 39,921,061 | |||||||||||||||||||
| Origination revenue | 1,064,530 | 1,970,217 | 4,394,237 | 1,970,217 | |||||||||||||||||||
| Total revenues | 28,148,491 | 21,120,930 | 78,711,777 | 42,705,904 | |||||||||||||||||||
| COST OF REVENUES (excluding depreciation and amortization stated below) | |||||||||||||||||||||||
| Cost of revenue (including stock-based compensation) | 2,187,551 | 3,356,976 | 7,649,844 | 4,819,926 | |||||||||||||||||||
| Related party cost of revenue | 430 | 7,981 | 2,568 | 7,981 | |||||||||||||||||||
| Total cost of revenue | 2,187,981 | 3,364,957 | 7,652,412 | 4,827,907 | |||||||||||||||||||
| Gross Profit | 25,960,510 | 17,755,973 | 71,059,365 | 37,877,997 | |||||||||||||||||||
| OPERATING EXPENSES: | |||||||||||||||||||||||
| Sales and marketing | 2,169,197 | 1,704,154 | 6,651,942 | 3,116,999 | |||||||||||||||||||
| General and administrative (including stock-based compensation) | 15,489,503 | 9,838,951 | 41,396,346 | 11,113,382 | |||||||||||||||||||
| Loss on change in fair value of debt | 124,237 | (2,088,797) | 4,036,327 | 309,865 | |||||||||||||||||||
| Unrealized loss (gain) on investments | (417,677) | 306,800 | (1,220,161) | (491,356) | |||||||||||||||||||
| Realized gain on investments | - | - | (856,744) | - | |||||||||||||||||||
| Depreciation and amortization expense | 1,745,279 | 1,694,853 | 5,177,785 | 1,696,994 | |||||||||||||||||||
| Total operating expenses | 19,110,539 | 11,455,961 | 55,185,495 | 15,745,884 | |||||||||||||||||||
| Operating Income | 6,849,971 | 6,300,012 | 15,873,870 | 22,132,113 | |||||||||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||||||||
| Loss on change in fair value of warrant liability | (8,766,500) | (943,400) | (8,487,040) | (943,400) | |||||||||||||||||||
| Interest expense | (4,218,314) | (2,679,237) | (12,417,946) | (3,620,695) | |||||||||||||||||||
| Interest income | 609,496 | 63,826 | 1,670,828 | 71,283 | |||||||||||||||||||
| Other (expense) income | (9,832) | 20,086 | 132,610 | (1,565) | |||||||||||||||||||
| Total other (expense) | (12,385,150) | (3,538,725) | (19,101,548) | (4,494,377) | |||||||||||||||||||
| Net (loss) income before provision for income taxes | (5,535,179) | 2,761,287 | (3,227,678) | 17,637,736 | |||||||||||||||||||
| Income tax (benefit) expense | (250,368) | 1,710,315 | 2,680,855 | 2,238,419 | |||||||||||||||||||
| NET (LOSS) INCOME | (5,284,811) | 1,050,972 | (5,908,533) | 15,399,317 | |||||||||||||||||||
| LESS: NET (LOSS) INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST | (159,756) | 147,611 | (204,716) | (339,692) | |||||||||||||||||||
| NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS | (5,125,055) | 903,361 | (5,703,817) | 15,739,009 | |||||||||||||||||||
| (LOSS) EARNINGS PER SHARE: | |||||||||||||||||||||||
(Loss) earnings per share - basic [1] | $ (0.07) | $ 0.01 | $ (0.09) | $ 0.29 | |||||||||||||||||||
(Loss) earnings per share - diluted [1] | $ (0.07) | $ 0.01 | $ (0.09) | $ 0.29 | |||||||||||||||||||
Weighted-average stock outstanding—basic [1] | 74,694,319 | 63,349,823 | 66,984,401 | 54,632,826 | |||||||||||||||||||
Weighted-average stock outstanding—diluted [1] | 74,694,319 | 63,349,823 | 66,984,401 | 54,632,826 | |||||||||||||||||||
[1] The 2023 number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of Abacus Life, Inc. as a result of the Business Combination.
ABACUS LIFE, INC. Adjusted Net Income and Adjusted EPS
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||
| NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ (5,125,055) | $ 903,361 | $ (5,703,817) | $ 15,739,009 | |||||||||||||||||||||||||
| Amortization expense | 1,698,983 | 1,682,083 | 5,072,125 | 1,682,083 | |||||||||||||||||||||||||
| Stock-based compensation | 6,416,378 | 4,583,632 | 18,675,208 | 4,583,632 | |||||||||||||||||||||||||
| Business acquisition costs | 1,948,118 | — | 3,273,118 | — | |||||||||||||||||||||||||
| Loss on change in fair value of warrant liability | 8,766,500 | 943,400 | 8,487,040 | 943,400 | |||||||||||||||||||||||||
Tax impact [1] | 1,174,328 | 908,271 | 3,518,782 | 908,271 | |||||||||||||||||||||||||
| Adjusted Net Income | $ 14,879,252 | $ 9,020,747 | $ 33,322,456 | $ 23,856,395 | |||||||||||||||||||||||||
Weighted-average shares of Class A common stock outstanding - basic [2] | 74,694,319 | 63,349,823 | 66,984,401 | 54,632,826 | |||||||||||||||||||||||||
Weighted-average shares of Class A common stock outstanding - diluted [2] | 74,694,319 | 63,349,823 | 66,984,401 | 54,632,826 | |||||||||||||||||||||||||
| Adjusted EPS - basic | $ 0.20 | $ 0.14 | $ 0.50 | $ 0.44 | |||||||||||||||||||||||||
| Adjusted EPS - diluted | $ 0.20 | $ 0.14 | $ 0.50 | $ 0.44 | |||||||||||||||||||||||||
[1] Tax impact represents the permanent difference in tax expense related to the restricted stock awards granted to the CEO due to IRC 162(m) limitations.
[2] The 2023 number of shares outstanding have been retrospectively recast for prior period presented to reflect the outstanding stock of Abacus Life, Inc. as a result of the Business Combination.
ABACUS LIFE, INC. Adjusted EBITDA
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||
| NET (LOSS) INCOME | $ (5,284,811) | $ 1,050,972 | $ (5,908,533) | $ 15,399,317 | |||||||||||||||||||||||||
| Depreciation and amortization expense | 1,745,279 | 1,694,853 | 5,177,785 | 1,696,994 | |||||||||||||||||||||||||
| Income tax (benefit) expense | (250,368) | 1,710,315 | 2,680,855 | 2,238,419 | |||||||||||||||||||||||||
| Interest expense | 4,218,314 | 2,679,237 | 12,417,946 | 3,620,695 | |||||||||||||||||||||||||
| Other (income) expense | 9,832 | (20,086) | (132,610) | 1,565 | |||||||||||||||||||||||||
| Interest income | (609,496) | (63,826) | (1,670,828) | (71,283) | |||||||||||||||||||||||||
| Loss on change in fair value of warrant liability | 8,766,500 | 943,400 | 8,487,040 | 943,400 | |||||||||||||||||||||||||
| Stock-based compensation | 6,416,378 | 4,583,632 | 18,675,208 | 4,583,632 | |||||||||||||||||||||||||
| Business acquisition costs | 1,948,118 | — | 3,273,118 | — | |||||||||||||||||||||||||
| Unrealized (gain) loss on equity securities, at fair value | (417,677) | 306,800 | (1,220,161) | (491,356) | |||||||||||||||||||||||||
| Realized gain on equity securities, at fair value | — | — | (856,744) | — | |||||||||||||||||||||||||
| Loss (gain) on change in fair value of debt | 124,237 | (2,088,797) | 4,036,327 | 309,865 | |||||||||||||||||||||||||
| Adjusted EBITDA | $ 16,666,306 | $ 10,796,500 | $ 44,959,403 | $ 28,231,248 | |||||||||||||||||||||||||
| Adjusted EBITDA margin | 59.2 % | 51.1 % | 57.1 % | 66.1 % | |||||||||||||||||||||||||
| Net (loss) income margin | (18.8) % | 5.0 % | (7.5) % | 36.1 % | |||||||||||||||||||||||||
ABACUS LIFE, INC. Adjusted Return on Invested Capital (ROIC)
| For the period ended | For the period ended | |||||||||||||
| June 30, 2024 | September 30, 2024 | |||||||||||||
| Total Assets | $ 483,854,905 | $ 477,309,168 | ||||||||||||
| Less: | ||||||||||||||
| Intangible assets, net | (26,352,123) | (24,653,141) | ||||||||||||
| Goodwill | (139,930,190) | (139,930,190) | ||||||||||||
| Total current liabilities | (55,383,057) | (23,862,348) | ||||||||||||
| Total Invested Capital | $ 262,189,535 | $ 288,863,489 | ||||||||||||
| Adjusted Net Income | $ 11,812,527 | $ 14,879,252 | ||||||||||||
| Adjusted Annualized ROIC | 18.0 % | 20.6 % | ||||||||||||
ABACUS LIFE, INC. Adjusted Return on Equity (ROE)
| For the period ended | For the period ended | |||||||||||||
| June 30, 2024 | September 30, 2024 | |||||||||||||
| Total stockholders' equity | $ 256,849,488 | $ 257,939,628 | ||||||||||||
| Adjusted Net Income | $ 11,812,527 | $ 14,879,252 | ||||||||||||
| Adjusted Annualized ROE | 18.4 % | 23.1 % | ||||||||||||